3530 JOHN HOPKINS COURT, SAN DIEGO, CA
Market cap: $5.9B (2/12/2026)
Price: $5.95
Reports Continued Execution and Sales Momentum With $113 Million of Preliminary Net Product Revenue—a 700% increase year-over-year
Saudi FDA Grants Accelerated Approval to ANKTIVA® for Non-Muscle Invasive Bladder Cancer with Carcinoma In-Situ
ImmunityBio, Inc. Enters Amendment to Sale Agreement for $459.97M Shares
Board Appointment - Bruce Wendel Joins ImmunityBio Board of Directors
ImmunityBio Gets EMA Nod for ANKTIVA® for Bladder Cancer
Driven by Strong Demand, Reports 467% Year-to-Date Unit Growth and $75 Million in Sales Year-to-Date, Up 434% from Q3 2024
Other Events
Reports Q2 Earnings Release Reflecting 60% Increase in Revenue in Q2 2025, with Year-to-Date Sales of $43 million and 246% Unit Growth Since J-code
Q3
Q2
Q1
FY 2024
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
Effectiveness Notice
Definitive Information Statement
Preliminary Information Statement
Additional Proxy Materials
Definitive Proxy Statement
Statement of Changes in Beneficial Ownership
Notice of Proposed Sale of Securities
Correspondence
Submission Upload